These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 26466651)

  • 21. Efficacy of the protease inhibitor BI 201335, polymerase inhibitor BI 207127, and ribavirin in patients with chronic HCV infection.
    Zeuzem S; Asselah T; Angus P; Zarski JP; Larrey D; Müllhaupt B; Gane E; Schuchmann M; Lohse A; Pol S; Bronowicki JP; Roberts S; Arasteh K; Zoulim F; Heim M; Stern JO; Kukolj G; Nehmiz G; Haefner C; Boecher WO
    Gastroenterology; 2011 Dec; 141(6):2047-55; quiz e14. PubMed ID: 21925126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reinventing HCV Treatment: Past and Future Perspectives.
    Carter W; Connelly S; Struble K
    J Clin Pharmacol; 2017 Mar; 57(3):287-296. PubMed ID: 27654843
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase III results of Boceprevir in treatment naïve patients with chronic hepatitis C genotype 1.
    Manns MP; Markova AA; Calle Serrano B; Cornberg M
    Liver Int; 2012 Feb; 32 Suppl 1():27-31. PubMed ID: 22212568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
    Asselah T; Marcellin P
    Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current Management of Hepatitis C Virus: Regimens for Peri-Liver Transplant Patients.
    Saxena V; Terrault N
    Clin Liver Dis; 2015 Nov; 19(4):669-88, vi. PubMed ID: 26466655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of chronic HCV genotype 1 coinfection.
    Boesecke C; Rockstroh JK
    Curr HIV/AIDS Rep; 2015 Sep; 12(3):326-35. PubMed ID: 26228050
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Asunaprevir-containing regimens for the treatment of hepatitis C virus infection.
    Yang SS; Kao JH
    Expert Rev Gastroenterol Hepatol; 2015 Jan; 9(1):9-20. PubMed ID: 25174254
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct-acting antivirals: the endgame for hepatitis C?
    D'Ambrosio R; Degasperi E; Colombo M; Aghemo A
    Curr Opin Virol; 2017 Jun; 24():31-37. PubMed ID: 28419938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir.
    Berger KL; Triki I; Cartier M; Marquis M; Massariol MJ; Böcher WO; Datsenko Y; Steinmann G; Scherer J; Stern JO; Kukolj G
    Antimicrob Agents Chemother; 2014; 58(2):698-705. PubMed ID: 24217701
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon free therapy with direct acting antivirals for HCV.
    Asselah T; Marcellin P
    Liver Int; 2013 Feb; 33 Suppl 1():93-104. PubMed ID: 23286852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase 2a trial of 12-week interferon-free therapy with two direct-acting antivirals (ABT-450/r, ABT-072) and ribavirin in IL28B C/C patients with chronic hepatitis C genotype 1.
    Lawitz E; Poordad F; Kowdley KV; Cohen DE; Podsadecki T; Siggelkow S; Larsen L; Menon R; Koev G; Tripathi R; Pilot-Matias T; Bernstein B
    J Hepatol; 2013 Jul; 59(1):18-23. PubMed ID: 23439262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiviral strategies in hepatitis C virus infection.
    Sarrazin C; Hézode C; Zeuzem S; Pawlotsky JM
    J Hepatol; 2012; 56 Suppl 1():S88-100. PubMed ID: 22300469
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors.
    Welzel TM; Dultz G; Zeuzem S
    J Hepatol; 2014 Nov; 61(1 Suppl):S98-S107. PubMed ID: 25443350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
    Everson GT; Sims KD; Rodriguez-Torres M; Hézode C; Lawitz E; Bourlière M; Loustaud-Ratti V; Rustgi V; Schwartz H; Tatum H; Marcellin P; Pol S; Thuluvath PJ; Eley T; Wang X; Huang SP; McPhee F; Wind-Rotolo M; Chung E; Pasquinelli C; Grasela DM; Gardiner DF
    Gastroenterology; 2014 Feb; 146(2):420-9. PubMed ID: 24184132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing triple therapy and IFN/RBV-free regimens for hepatitis C virus infection.
    Chayama K; Mitsui F; Hayes CN
    Expert Rev Gastroenterol Hepatol; 2015 Jan; 9(1):21-30. PubMed ID: 25220206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potent Antiviral Activities of the Direct-Acting Antivirals ABT-493 and ABT-530 with Three-Day Monotherapy for Hepatitis C Virus Genotype 1 Infection.
    Lawitz EJ; O'Riordan WD; Asatryan A; Freilich BL; Box TD; Overcash JS; Lovell S; Ng TI; Liu W; Campbell A; Lin CW; Yao B; Kort J
    Antimicrob Agents Chemother; 2015 Dec; 60(3):1546-55. PubMed ID: 26711747
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents.
    Conteduca V; Sansonno D; Russi S; Pavone F; Dammacco F
    J Infect; 2014 Jan; 68(1):1-20. PubMed ID: 24012819
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regimens for Patients Coinfected with Human Immunodeficiency Virus.
    Wyles DL
    Clin Liver Dis; 2015 Nov; 19(4):689-706, vi-vii. PubMed ID: 26466656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fixed-dose combination of sofosbuvir and ledipasvir for the treatment of chronic hepatitis C genotype 1.
    Kumari R; Nguyen MH
    Expert Opin Pharmacother; 2015 Apr; 16(5):739-48. PubMed ID: 25676581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interferon-combination strategies for the treatment of chronic hepatitis C.
    Aronsohn A; Jensen D
    Semin Liver Dis; 2014 Feb; 34(1):30-6. PubMed ID: 24782256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.